[1] Chancharoenthana W,Townamchai N,Pongpirul K,et al.The outcomes of kidney transplantation in hepatitis B surface antigen(HBsAg)-negative recipients receiving graft from HBsAg-positive donors:a retrospective,propensity score-matched study. Am J Transplant,2014,14(12):2814-2820.
[2] Malik MU,Ucbilek E,Trilianos P,et al.Prophylaxis among hepatitis B core antibody-positive deceased-donor liver transplant recipients:Hepatitis B immunoglobulin plus oral antiviral agents versus antiviral agents alone:A single-center experience. Exp Clin Transplant,2017,15(2):183-188.
[3] özgüler M,Akbulut A,Demirdag K,et al. Investigation by the method of INNO-LiPA of primary resistance to lamivudine in patients with chronic hepatitis B who have not used antiviral therapy. West Indian Med J,2015,65(1):111-115.
[4] 包依夏姆·阿巴拜克力,努力比亚·阿不杜克尤木,张跃新. 乙肝疫苗联合HBIG接种阻断HBsAg/HBeAg双阳性孕妇HBV母婴传播的效果研究. 实用肝脏病杂志,2017,20(4):481-482.
[5] Kao JH,Asselah T,Dou XG,et al.Telbivudine therapy for chronic hepatitis B:A journey to identify super-responders and to optimize treatment using the roadmap model. J Gastroenterol Hepatol,2017,32(1):73-81.
[6] An J,Lim YS,Kim GA,et al.Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA:a randomized trial. BMC Gastroenterol,2017,17(1):15.
[7] Biot B,Laverdure N,Lacaille F,et al.Mother-to-child transmission of hepatitis B virus despite postexposure prophylaxis:A review of the literature and description of 11 observations. Arch Pediatr,2017,24(2):135-139.
[8] 毕毅强. 替比夫定治疗HBeAg阳性慢性乙型肝炎疗效观察. 实用肝脏病杂志,2014,17(4):410-411.
[9] Turan I,Yapali S,Bademkiran F,et al.Telbivudine in liver transplant recipients:Renal protection does not overcome the risk of polyneuropathy and myopathy. Liver Transpl,2015,21(8):1066-1075.
[10] Emery JS,Feld JJ.Treatment of hepatitis B virus with combination therapy now and in the future. Best Pract Res Clin Gastroenterol,2017,31(3):347-355. |
